AI-powered virtual assistant will be used to streamline entire pre- and post-vaccine distribution process for patients
San Francisco, CA, December 22, 2020 – Following recent FDA approval of the first two COVID-19 vaccines, GYANT, the AI-powered virtual assistant company, today announced that its vaccine care navigation tool, GYANT Vaccine, has continued to gain traction since its launch in October. The solution is being deployed by numerous health systems, including CHRISTUS Health, Hackensack Meridian Health, MLK Community Healthcare, and Edward-Elmhurst Health, to facilitate the pre- and post-vaccine process in the weeks and months ahead.
With the Pfizer vaccine FDA approved and already being distributed, and Moderna’s vaccine recently granted Emergency Use Authorization, health systems are looking to virtual assistants to build an infrastructure to efficiently manage each stage of rollout. GYANT Vaccine virtually guides patients through the entire pre- and post-vaccination process, from screening to scheduling and proactive follow-ups, to alert patients about eligibility and monitor potential side effects. The solution helps health systems pre-qualify individuals and facilitate deployment in direct alignment with phased or prioritized availability. Moreover, it adapts to each provider’s changing requirements over the course of the vaccine rollout.
As vaccines are approved and production and distribution increase, states will continue to update vaccination policies and procedures. Health systems are thinking ahead by incorporating GYANT’s automated patient education and care navigation to minimize communication workloads, administrative overhead, and keep their providers focused on fighting the pandemic.
“Since vaccine approval, we’ve had strong traction amongst the nation’s leading health systems,” said Stefan Behrens, co-founder and CEO, GYANT. “Patients are eager to reach the other side of the pandemic and intend to get vaccinated as soon as possible. Health systems recognize and are beginning to experience the forthcoming onslaught of patient inquiries about vaccines. We are proud to help manage this overwhelming demand, freeing provider time for meaningful care and streamlining vaccine communication.”
“Putting the patient experience at the forefront of our deployment strategy has been a priority,” said Cheryl Eck, Associate Vice President Strategy & Planning at Edward-Elmhurst Health. “GYANT Vaccine empowers patients to get the information they need to understand more about the vaccine and its rollout.”
For more information on GYANT Vaccine, visit https://gyant.com/vaccine.
GYANT’s empathic, intuitive virtual assistant guides patients through the complexity of their healthcare systems. With dozens of clients throughout the United States, GYANT partners with Integrated Delivery Networks to deploy its technology on their websites, mobile apps, and patient portals, empowering patients to take control and connect the dots across their digital journeys and more meaningfully engage with their providers any time of the day, every day of the year. GYANT reduces clinical strain and support staff overhead, improves outcomes, and exceeds patient expectations. GYANT’s conversational AI handholds patients from the virtual front door through their entire clinical journey by integrating deeply into clinical workflows (EHRs). The result is a higher level of efficiency that improves patient outcomes and makes them feel truly valued, now and every time they return. Some of GYANT’s customers include Intermountain Healthcare, OSF HealthCare, Adventist Health, Cleveland Clinic, and Geisinger. https://gyant.com/